使用"Epilepto"提高耐药性的药物坚持:一个试点随机对照试验 (EMPOWER-E)
Paras Tewari1, Saurabh Agarwal1, Lokesh Saini1
1Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
一个提供药物提醒的移动应用程序改善了耐药的儿童的药物坚持. 虽然遗忘是一个障碍,但该应用程序显示出更好的药物遵守的承诺.
科学领域:
- 儿科神经学 儿科神经学
- 数字健康数字健康
- 药理学依从性 药理学依从性
背景情况:
- 耐药性严重影响儿童的生活质量.
- 药物不服药,通常是由于遗忘,加剧了的负担.
- 需要有效的策略来改善儿科的药物服药.
研究的目的:
- 为了评估移动应用程序"Epilepto"在改善药物耐药的儿童中药物坚持的有效性.
- 评估移动药物提醒对发作负担的影响.
- 确定在这个人群中使用移动应用程序用于药物管理的可行性和可接受性.
主要方法:
- 一项随机对照试验,涉及100名患有耐药的儿童 (3个月至18岁).
- 干预组使用"Epilepto"应用程序进行药物提醒;对照组接受标准护理.
- 药物坚持 (莫里斯基药物坚持量-8) 和重 (幼儿严重程度量) 被评估在3个月和6个月.
主要成果:
- 干预组在6个月的时间内显示高药物坚持率增加了30%,而对照组在6个月的时间内增加了6%.
- 大多数用户 (81.2%) 发现药物提醒是可以接受和有用的.
- 在研究结束时,研究小组之间没有观察到明显减少发作负担.
结论:
- 通过"Epilepto"应用程序的移动药物提醒是改善药物耐药儿童服药的可行和可接受的干预措施.
- 虽然坚持性有所改善,但需要进一步的研究,以将其与减少发作负担相关联.
- 数字健康工具显示出在儿童群体中治疗慢性疾病的潜力.
更多相关视频
05:54Stereo-Electro-Encephalo-Graphy SEEG With Robotic Assistance in the Presurgical Evaluation of Medical Refractory Epilepsy: A Technical Note
Published on: June 13, 2016
09:06Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Drug Therapy
Antianxiety Medications
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
